RecruitingOverweightObesity
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Eligible age
18–65 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Sponsor: Novo Nordisk A/S
You may qualify if…
- ✓ 1. Male or female (sex at birth).
- ✓ 2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
- ✓ For Japanese participants: both parents of Japanese descent.
- ✓ For Chinese participants: both parents of Chinese descent.
- ✓ For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
- ✓ 3. Age at the time of signing the informed consent:
- ✓ 1. For Part A: 18-55 years (both inclusive)
- ✓ 2. For Part B: 18-65 years (both inclusive)
You may not qualify if…
- ✕ 1. Known or suspected hypersensitivity to study intervention(s) or related products.
- ✕ 2. Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
- ✕ 3. Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
Where it's recruiting
California
Cypress
Kansas
Overland Park
Source: ClinicalTrials.gov · NCT07395687 · last updated 2026-04-21